For the Inventor, By the Inventor

Enter inventor name

Osamu Nureki

USPTO Granted Patents = 13 (Patent Applications = 7)

EPO Patents = 1 (Patent Applications = 8)

Average Co-Inventor Count = 6.4

ph-index = 3

Forward Citations = 25(Granted Patents)

Location History:

Bunkyo-ku, JP (2022)
Kanagawa, JP (2009 - 2023)
Tokyo, JP (2019 - 2023)
Yokohama, JP (2023)

Company Filing History:

12 out of 1,285

The University of Tokyo

The Broad Institute, Inc.

Massachusetts Institute of Technology

4. 5 out of 2,963

Harvard College

5. 2 out of 984

Tohoku University

6. 2 out of 1,001

Shionogi Company Limited

Modalis Therapeutics Corporation

8. 1 out of 1,310

Japan Science and Technology Agency

9. 1 out of 854

Riken Corporation

10. 1 out of 229

Mochida Pharmaceutical Co., Ltd.

where one patent can have more than one assignee

Years Active: 2009-2025

Loading Chart...

Loading Chart...

13 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12258595 - Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems (2025-03-25),

2. 12168789 - Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation (2024-12-17),

3. 12152259 - Modified CAS9 protein, and use thereof (2024-11-26),

4. 11702645 - Polynucleotide encoding modified CAS9 protein (2023-07-18),

5. 11597919 - Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems (2023-03-07),

6. 11578312 - Engineering and optimization of systems, methods, enzymes and guide scaffolds of CAS9 orthologs and variants for sequence manipulation (2023-02-14),

7. 11530396 - Modified CAS9 protein, and use thereof (2022-12-20),

8. 11371030 - Modified Cas9 protein and use thereof (2022-06-28),

9. 11155795 - CRISPR-Cas systems, crystal structure and uses thereof (2021-10-26),

10. 10550372 - Systems, methods and compositions for sequence manipulation with optimized functional CRISPR-Cas systems (2020-02-04),

11. 10189843 - Fused pyrazole derivative having autotaxin inhibitory activity (2019-01-29),

12. 10183949 - Pyrimidinone derivative having autotaxin-inhibitory activity (2019-01-22),

13. 7514240 - EGR-EGFR complex (2009-04-07),

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…